- Annovis Bio tripled Friday after reporting exciting Alzheimer's data.
- Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-? precursor protein from translating toxic A?.
- Posiphen looks promising in Alzheimer's, Parkinson's, Downs, and stroke recovery, but it does not address Alzheimer's disease at its root.
- Cassava's simufilam has better and stronger data with a treatment specific to Alzheimer's pathology, and may be able to stop the continual decline of the disease over the long term.
- Posiphen has patent applications, but a patent cliff in 2026.
For further details see:
Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better